HIGHLIGHTS
- who: Laurent Peyrin-Biroulet from the Medical Department, University Hospital Erlangen, Friedrich-AlexanderUniversity of Erlangen-Nu00fcrnberg, Ulmenweg, Erlangen, Germany have published the research: Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis, in the Journal: (JOURNAL) of 30/04/2021
- what: Consistent with these findings, this study demonstrated the similar patterns of outcomes even when the authors included the most recent data from infliximab and vedolizumab studies (i.e., VISIBLE, VARSITY, the CT-P13 SC trial). Potential limitations of the review process include . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.